Treatment of tumor-induced hypercalcemia: A solved problem?

Expert Review of Anticancer Therapy

Volumn 3, Issue 2, 2003, Pages 241-246

  Body, Jean Jacques ^a   Mancini, Isabelle ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Bisphosphonates; Bone metastasis; Cancer; Hypercalcemia; Osteolysis; Paraneoplastic syndrome; Parathyroid; PTH; PTHrP; Supportive care

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM ION; CLODRONIC ACID; CORTICOSTEROID; FUROSEMIDE; HORMONE ANTIBODY; IBANDRONIC ACID; MITHRAMYCIN; NERIDRONIC ACID; OLPADRONIC ACID; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PREDNISONE; RISEDRONIC ACID; SODIUM CHLORIDE; ZOLEDRONIC ACID;

ALBUMIN BLOOD LEVEL; BONE METASTASIS; BREAST CANCER; CLINICAL TRIAL; CONSTIPATION; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EXTRACELLULAR CALCIUM; FEVER; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; LUNG CANCER; NAUSEA; NONHUMAN; POLYDIPSIA; POLYURIA; RECURRENT DISEASE; REHYDRATION; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME; VOMITING;

EID: 0037392630     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.2.241     Document Type: Review

References (32)

1. Body JJ. Current and future directions in medical therapy: hypercalcemia. Cancer 88 (12 Suppl.), 3054-3058 (2000).
2. Body JJ, Bartl R, Burckhardt P et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J. Clin. Oncol. 16(12), 3890-3899 (1998).
3. De Wit S, Cleton F. Hypercalcemia in patients with breast cancer: a survival study. J. Cancer Res. Clin. Oncol. 120(10), 610-614 (1994).
4. Body JJ, Delmas PD. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J. Clin. Endocrinol. Metab. 74(3), 471-475 (1992).
5. Grill V, Ho P, Body JJ et al. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J. Clin. Endocrinol. Metab. 73(6), 1309-1315 (1991).
6. Dumon JC, Wantier H, Mathieu F et al. Technical and clinical validation of a new immunoradiometric assay for human osteocalcin. Eur. J. Endocrinol. 135 (2), 231-237 (1996).
7. Singer F, Ritch P, Lad T et al. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. Arch. Intern. Med. 151(3), 471-476 (1991).
8. Hosking D, Gilson D. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy. QJM 53(211), 359-368 (1984).
9. Gucalp R, Ritch P, Wiernik Ph et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J. Clin. Oncol. 10(1), 134-142 (1992).
10. Dumon JC, Magritte A, Body JJ. Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner. 15(3), 257-266 (1991).
11. O'rourke N, Mccloskey E, Vasikaran S et al. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br. J. Cancer 67(3), 560-563 (1993).
12. Shah S, Hardy J, Rees E et al. Is there a dose-response relationship for clodronate in the treatment of tumour induced hypercalcaemia? Br. J. Cancer 86(8), 1235-1237 (2002).
13. Purohit O, Radstone C, Anthony C et al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br. J. Cancer 72(5), 1289-1293 (1995).
14. Walker P, Watanabe S, Lawlor P et al. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Ann. Oncol. 8(9), 915-916 (1997).
15. Nussbaum S, Younger J, Vandepol C et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60- and 90-mg dosages. Am. J. Med. 95(3), 297-304 (1993).
16. Body JJ, Dumon JC. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type. Ann. Oncol. 5(4), 359-363 (1994).
17. Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 341(8861), 1611-1613 (1993).
18. Rizzoli R, Thiebaud D, Bundred N et al. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J. Clin. Endocrinol. Metab. 84(10), 3545-3550 (1999).
19. Body JJ, Louviaux I, Dumon JC. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. Support Care Cancer 8(5), 398-404 (2000).
20. Green J, Muller K, Jaeggi K. Preclinical pharmacology of CGP 42'446, a new potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. 9(5), 745-751 (1994).
21. Pecherstorfer M, Herrmann Z, Body JJ et al. Randomized Phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J. Clin. Oncol. 14(1), 268-276 (1996).
22. Ralston SH, Thiebaud D, Herrmann Z et al. Dose-response study of ibandronate in the treatment of cancer- associated hypercalcaemia. Br. J. Cancer 75(2), 295-300 (1997).
23. Pecherstorfer M, Steinhauer E, Pawsey S. Ibandronic acid is more effective than pamidronate in lowering serum calcium in patients with severe hypercalcemia of malignancy (HCM) and has at least equal efficacy to pamidronate in HCM patients with lower baseline calcium levels: results of a randomised, open label, comparative study. Proc. ASCO 20, 385a (2001) (Abstract 1535).
24. Body JJ, Lortholary A, Romieu G et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J. Bone Miner. Res. 14(9), 1557-1561 (1999).
25. Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. 19(2), 558-567 (2001).
26. Hofbauer L. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur. J. Endocrinol. 141(3), 195-210 (1999).
27. Capparelli C, Kostenuik P, Morony S et al. Comparison of osteoprotegerin and pamidronate in a murine model of humoral hypercalcemia of malignancy. J. Bone Miner. Res. 14(Suppl. 1), S163 (1999).
28. Body JJ, Greipp P, Coleman R et al. A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97(Suppl. 3), 887-892 (2003).
29. Hortobagyi G, Theriault R, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J. Clin. Oncol. 16(6), 2038-2044 (1998).
30. Berenson J, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J. Clin. Oncol. 16(2), 593-602 (1998).
31. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. (In Press).
32. Body J. Dosing regimens and main adverse events of bisphosphonates. Semin. Oncol. 28(4) (Suppl. 11), 49-53 (2001).